利拉鲁肽治疗肥胖型2型糖尿病的临床疗效观察

目的观察利拉鲁肽治疗肥胖型2型糖尿病的临床疗效及安全性。方法选取2011年10月至2012年10月在武汉大学人民医院内分泌科就诊的口服降糖药物血糖控制不佳的肥胖型2型糖尿病患者21例，患者停用其他口服降糖药，改用利拉鲁肽，治疗3个月后比较治疗前后患者空腹血糖、餐后2h血糖、糖化血红蛋白A1c（1-IbA1c）、eC肽及体质量指数（BMI）的变化并记录低血糖等不良事件。结果治疗后患者的HbA1c、空腹血糖、餐后2h血糖、BMI均较治疗前有所下降，差异有统计学意义（P〈0．05），空腹ec肽、餐后2heC肽均有所升高，差异有统计学意义（P〈0．05）；患者无低血糖发生，部分患者有恶心、腹胀等胃肠道不良反应，但均可耐受。结论肥胖型2型糖尿病患者给予利拉鲁肽治疗安全有效，值得推广应用。

Liraglutide Efficacy on Treatment for Obesity Type 2 Diabetes

Objective To evaluate the efficacy and safety of liraglutide on obesity type 2 diabetic patients. Methods From Oet. 2011 to Oct. 2012 of Renmin Hospital of Wuhan University, 21 obesity patients with type 2 diabetes whose blood glucose were not well controlled by taking oral drugs were selected and given liraglutide therapy for 3 months by discontinuing the basal therapeutic measures. FPG, 2 hPG, HbAlc ,C-peptide and BMI were compared with before the treatment and the adverse events sueh as hypogly- eemia were recorded. Results After 3 months treatment, HbAlc, FPG,2 hPG and BMI were reduced （P 〈 0.05 ）. Fasting and postprandial C-peptide level were increased （ P 〈 O. 05 ）. No hypoglycemia occurred. Minority patients had nausea and discomfort of gastrointestinal symptoms within endurance. Conehmion Obesity type 2 diabetes mellitus treated by liraglutide therapy sees safe and effective resuh,whieh is worthy of promotion.